CORRECTION



Correction to: Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

Kirk Haltaufderhyde¹ · Brian J. Roberts¹ · Sundos Khan¹ · Frances Terry¹ · Christine M. Boyle¹ · Mitchell McAllister¹ · William Martin¹ · Amy Rosenberg¹ · Anne S. De Groot^{1,2}

Published online: 19 December 2023 © The Author(s) 2023

Correction to: The AAPS Journal (2023) 25:87 https://doi.org/10.1208/s12248-023-00852-z

The original article has been updated to correct a statement "The general guidelines for the maximum amount of allowed HCP impurities is 100 ng per mg of HCP." to "The general guidelines for the maximum amount of allowed HCP impurities is 100 ng per mg of product."

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at https://doi.org/10.1208/ \pm 12248-023-00852-z.

- Anne S. De Groot
 AnnieD@EpiVax.com
- EpiVax, Inc, 188 Valley St #424, Providence, Rhode Island, USA
- ² Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA



